<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03735368</url>
  </required_header>
  <id_info>
    <org_study_id>2018/10/15/5</org_study_id>
    <nct_id>NCT03735368</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine and Pregabalin for Conscious Sedation During Cataract Surgery</brief_title>
  <official_title>Dexmedetomidine With or Without Pregabalin Premedication for Conscious Sedation During Cataract Surgery Under Topical Anesthesia. A Randomized Double-blind Placebo-controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abd-Elazeem Abd-Elhameed Elbakry</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menoufia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although topical anesthesia by eye drops for cataract surgery is a non-invasive technique but
      it may provide insufficient anesthesia which requires the intraoperative use of additional
      topical local anesthetics and raises the need for sedation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study is constructed to evaluate the effect of pregabalin on sedation using
      dexmedetomidine for cataract surgery under topical anesthesia . In the
      dexmedetomidine-pregabalin group, the patients will be premedicated by pregabalin. In the
      placebo group (control group) the patients will be premedicated by placebo capsules. All
      patients will be sedated by dexmedetomidine. Sedation will be assessed as a primary outcome
      measurement where pain, vital signs, intraoperative and postoperative pain, total analgesic
      needs and side effects will be assessed as secondary outcome measurements.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 10, 2018</start_date>
  <completion_date type="Actual">November 29, 2019</completion_date>
  <primary_completion_date type="Actual">October 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The patients, the surgeons and the research team will be blinded to the randomization.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>sedation score changes</measure>
    <time_frame>baseline,1hour after premedication, intraoperative every 5 minutes ,postoperative every 6hours for 24 hours</time_frame>
    <description>Ramsay sedation score from 1 to 6. score 2 to 4 is acceptable sedation. Score 5 or 6 is excessive sedation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain score changes</measure>
    <time_frame>baseline,1hour after premedication, intraoperative every 5 minutes ,postoperative every 6hours for 24 hours</time_frame>
    <description>verbal pain score (VPS) from 0 = no pain to 10= the worst pain imaginable. scor ≥ 3 indicates need of analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate changes</measure>
    <time_frame>baseline,1hour after premedication, intraoperative every 5 minutes ,postoperative every 6hours for 24 hours</time_frame>
    <description>beats/minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial blood pressure changes</measure>
    <time_frame>baseline,1hour after premedication, intraoperative every 5 minutes ,postoperative every 6hours for 24 hours</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial oxygen saturation</measure>
    <time_frame>baseline,1hour after premedication, intraoperative every 5 minutes ,postoperative every 6hours for 24 hours</time_frame>
    <description>the percentage of hemoglobin saturation with oxygen in arterial blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory rate</measure>
    <time_frame>baseline,1hour after premedication, intraoperative every 5 minutes ,postoperative every 6hours for 24 hours</time_frame>
    <description>breath/minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total dexmedetomidine consumption</measure>
    <time_frame>intraoperatively</time_frame>
    <description>ug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of respiratory depression</measure>
    <time_frame>from administering premedication till 24 hours postoperative.</time_frame>
    <description>percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypotension</measure>
    <time_frame>from administering premedication till 24hours postoperative</time_frame>
    <description>percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of bradycardia</measure>
    <time_frame>from administering premedication till 24hours postoperative</time_frame>
    <description>percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ataxia</measure>
    <time_frame>from administering premedication till 24hours postoperative</time_frame>
    <description>percentage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Conscious Sedation</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo oral capsule+ dexmedetomidine+topical anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine- Pregabalin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pregabalin Oral Capsule +Dexmedetomidine Injection+topical anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Injection</intervention_name>
    <description>Dexmedetomidine Injection 1 μg/kg then 0.5-1 μg/kg/h infusion</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Dexmedetomidine- Pregabalin</arm_group_label>
    <other_name>Dexmedetomidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>placebo oral capsules</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin Oral Capsule</intervention_name>
    <description>150 mg pregabalin Oral Capsule</description>
    <arm_group_label>Dexmedetomidine- Pregabalin</arm_group_label>
    <other_name>pregabalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topical anesthesia</intervention_name>
    <description>topical anesthesia of the eye by Benoxinate Hydrochloride 0.4% Eye Drops</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Dexmedetomidine- Pregabalin</arm_group_label>
    <other_name>Benoxinate Hydrochloride 0.4% Eye Drops</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society Of Anesthesiologists (ASA) I and II physical status.

          -  Scheduled for cataract extraction under topical anesthesia.

        Exclusion Criteria:

          -  Hepatic or renal impairment.

          -  Taking chronic psychotropic medications.

          -  Mental instability.

          -  Morbid obesity.

          -  Alcohol abuse.

          -  Substance abuse.

          -  Pregnant and lactating females.

          -  History of allergy to the study drugs used
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abd-Elazeem A Elbakry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Cairo</city>
        <state>Shebin El-kom</state>
        <zip>32511</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 4, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>December 25, 2019</last_update_submitted>
  <last_update_submitted_qc>December 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Menoufia University</investigator_affiliation>
    <investigator_full_name>Abd-Elazeem Abd-Elhameed Elbakry</investigator_full_name>
    <investigator_title>assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Benoxinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

